Bringing the Oncology Community Together

Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab

Jill Stein
Published Online: Thursday, December 22, 2011
Robert Pirker, MD

Robert Pirker, MD

Investigators reported that high tumor epidermal growth factor receptor (EGFR) expression is a predictive biomarker that defines patients with advanced non–small cell lung cancer (NSCLC) who are most likely to derive a survival benefit from the addition of cetuximab to platinum-based, first-line chemotherapy.

“To our knowledge, this is the first study to show that tumor EGFR expression level is associated with survival benefit for a targeted therapy given concurrently with first-line chemotherapy in patients with advanced NSCLC,” said Robert Pirker, MD, with the Medical University of Vienna in Austria, and associates.

For their study, the group examined the association of tumor EGFR expression level with clinical outcome in patients enrolled in the phase III First-Line Erbitux in Lung Cancer (FLEX) study.

They pointed out that attention has been increasingly focused on the identification of predictive tumor biomarkers in order to improve the benefit-risk ratio of anticancer treatments. Ultimately, these biomarkers can help refine the selection of patients who are likely to benefit most from treatment.

The FLEX study had already shown that patients with EGFR-expressing, advanced NSCLC who had been randomized to the EGFR inhibitor cetuximab on top of chemotherapy involving cisplatin and vinorelbine had a superior overall survival (OS) than patients assigned to chemotherapy alone (hazard ratio [HR], 0.871; 95% CI 0.762-0.996; P =.044).

In the present analysis, the researchers used an immunohistochemistry scoring system in which a score <200 indicated low EGFR expression while a score ≥200 denoted high EGFR expression.

High EGFR expression was scored for 345 (31%) of 1121 patients in whom tumor EGFR expression data were available and low EGFR expression for 776 (69%) patients.

Median OS was longer in the high EGFR expression group in the cetuximab-pluschemotherapy arm compared with the chemotherapy-alone arm (median of 12.0 mo [95% CI, 10.2-15.2] vs 9.6 mo [CI, 7.6-10.6]; HR, 0.73; CI, 0.58-0.93; P =.011).

The improved OS in the cetuximab-pluschemotherapy, high-EGFR group was achieved without an appreciable increase in side effects. There was no OS benefit in the low-EGFRexpression group (a median of 9.8 mo [CI, 8.9- 12.2] vs 10.3 mo [CI, 9.2-11.5]; HR, 0.99; CI, 0.84- 1.16; P =.88).

Extended OS in the chemotherapy-pluscetuximab group was observed for patients with high EGFR expression in all major NSCLC histological subgroups that were examined.

The authors said that the clinically meaningful improvements in survival and benefit-risk ratio in patients with high tumor EGFR expression in the diverse population of patients enrolled in the FLEX study provide a strong rationale for the use of EGFR expression in clinical practice to identify which patients with advanced NSCLC will benefit from the addition of cetuximab to first-line chemotherapy.

Related Articles
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Institute Develops Fresh Bench-to-Bedside Model Through Community Ties
In more than 40 years as a National Cancer Institute (NCI)-designated cancer center—and the first center in the network devoted purely to basic research—The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.